Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Plasma-Cell Myeloma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT00834665
What this trial is testing

Phase I/II Clinical Trial Combining hTERT Tumor Vaccine & Autologous T Cells in Patients With Advanced Myeloma

Who this might be right for
Multiple Myeloma
University of Pennsylvania 59
Testing effectiveness (Phase 2)UnknownNCT05493800
What this trial is testing

Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCT

Who this might be right for
Oral MucositisLymphomaMultiple Myeloma+1 more
MitoImmune Therapeutics 60
Testing effectiveness (Phase 2)Ended earlyNCT01670994
What this trial is testing

QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Altor BioScience 6
Early research (Phase 1)Active Not RecruitingNCT05286229
What this trial is testing

Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan

Who this might be right for
Relapsed/Refractory Multiple Myeloma
AbbVie 8
Testing effectiveness (Phase 2)Study completedNCT00779922
What this trial is testing

Pharmacokinetics of Lenalidomide (Revlimid®) in Patients With Multiple Myeloma and Impaired Renal Function

Who this might be right for
Multiple MyelomaImpaired Renal Function
Poitiers University Hospital 39
Early research (Phase 1)Study completedNCT01582295
What this trial is testing

XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease

Who this might be right for
Multiple Myeloma
Massachusetts General Hospital 4
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439266
What this trial is testing

Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 5
Large-scale testing (Phase 3)Active Not RecruitingNCT03617731
What this trial is testing

Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)

Who this might be right for
Multiple Myeloma
University of Heidelberg Medical Center 662
Testing effectiveness (Phase 2)Ended earlyNCT05427812
What this trial is testing

Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed/Refractory Multiple Myeloma
Ichnos Sciences SA 29
Not applicableLooking for participantsNCT05706766
What this trial is testing

Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Who this might be right for
Multiple MyelomaStem Cell Transplant Complications
Dana-Farber Cancer Institute 30
Not applicableNot Yet RecruitingNCT06888856
What this trial is testing

Multiple Myeloma is a Hematologic Malignancy Characterized by the Accumulation of Malignant Plasma Cells in the Bone Marrow. Despite Advances in Treatment, Many Patients Experience Disease Relapse. Bispecific Antibodies Offer an Innovative Therapeutic Approach, But Approximately 30%-40% of Patients

Who this might be right for
Multiple Myeloma (MM)
Tel-Aviv Sourasky Medical Center 200
Early research (Phase 1)Study completedNCT04163107
What this trial is testing

Combined Carfilzomib and Hydroxychloroquine in Patients With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Norwegian University of Science and Technology 19
Testing effectiveness (Phase 2)Ended earlyNCT03683277
What this trial is testing

IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic

Who this might be right for
Multiple MyelomaRelapsed and Refractory Multiple MyelomaGenetic Condition
Intergroupe Francophone du Myelome 26
Large-scale testing (Phase 3)Looking for participantsNCT07138209
What this trial is testing

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Qilu Pharmaceutical Co., Ltd. 228
Testing effectiveness (Phase 2)Looking for participantsNCT02727803
What this trial is testing

Personalized NK Cell Therapy in CBT

Who this might be right for
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Biphenotypic LeukemiaAcute Lymphoblastic Leukemia+23 more
M.D. Anderson Cancer Center 100
Testing effectiveness (Phase 2)Ended earlyNCT00039754
What this trial is testing

A Trial of Skeletal Targeted Radiotherapy Using Holmium-166-DOTMP in Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Poniard Pharmaceuticals
Not applicableStudy completedNCT01804140
What this trial is testing

A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)

Who this might be right for
Multiple Myeloma, Neoplasms
Genentech, Inc. 662
Testing effectiveness (Phase 2)UnknownNCT03090659
What this trial is testing

LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma

Who this might be right for
Refractory or Relapsed Multiple Myeloma
Nanjing Legend Biotech Co. 100
Early research (Phase 1)Study completedNCT05243342
What this trial is testing

Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Genentech, Inc. 18
Early research (Phase 1)UnknownNCT05549973
What this trial is testing

Anlotinib Hydrochloride Capsule Monotherapy and Combination Therapy Relapsed and Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China 32
Next Page